In Segment A, individuals will acquire various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional contributors will probably be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 is going to be offered as "incorporate-on" therapy. In https://dominickymxit.gynoblog.com/31314541/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing